key: cord-1015113-fv7z0du9
authors: Ozcelik, Fatih; Tanoglu, Alpaslan; Guven, Bulent Barıs; Keskin, Umran; Kaplan, Mustafa
title: Assessment of severity and mortality of COVID‐19 with anti‐A1 and anti‐B IgM isohaemagglutinins, a reflection of the innate immune status
date: 2021-07-29
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14624
sha: 8ab301834de96d8d388fd0890d688761e81afce9
doc_id: 1015113
cord_uid: fv7z0du9

AIMS: The relationship between the innate immune system that creates the polysaccharide antibody response and COVID‐19 is not fully understood. In this study, it was aimed to determine the predictive values of isohaemagglutinins in COVID‐19 severity/mortality. METHODS: Approximately 15 440 patients diagnosed with COVID‐19 were examined, and a total of 286 patients with anti‐B and anti‐A1 IgM isohaemagglutinins test results were randomly enrolled in the study. These patients were stratified into two groups according to anti‐A1 (n: 138 blood type B or O) and anti‐B (n: 148 blood type A) IgM isohaemagglutinins. Anti‐A1 or/and anti‐B IgM, biochemical parameters, symptoms, chronic diseases, hospitalisation status, intubation status, admission to intensive care unit (ICU) and exitus status were recorded and evaluated for all patients. RESULTS: Anti‐A1 IgM and anti‐B IgM were significantly lower in ICU patients (7.5 ± 9.9 vs 18.0 ± 20.4 and 5.5 ± 6.3 vs 19.3 ± 33.6 titres, respectively; P < .01) and in exitus patients (3.8 ± 3.6 vs 16.7 ± 18.7 and 3.5 ± 4.7 vs 16.9 ± 29.6 titres respectively; P < .01). In the ROC analysis performed to differentiate between exitus and discharge within groups, the sensitivity of anti‐B IgM and anti‐A1 IgM at cut‐off ≤4 was 88.9% and 79.6%, specificity 66.0% and 73.4%, and AUC 0.831 and 0.861, respectively (P < .01). Anti‐A1 IgM decreased the mortality risk 0.811 times per unit while anti‐B IgM decreased 0.717 times (P < .01). CONCLUSION: Anti‐B and anti‐A1 isohaemagglutinins, which are an expression of the innate immune system, can be used to predict the severity and mortality of COVID‐19 disease.

severity and duration by stimulating variable pro-inflammatory molecules and later activating the acquired immune system. 2, 3 Previously, it was found that pathogenic microbes can develop complex molecular strategies that disrupt host defences by affecting inflammatory signaling. 4, 5 Corona viruses also cause deadly diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and COVID-19 by overcoming the host antiviral defence with similar strategies. 6 This has prompted researchers to search for new biomarkers associated with disease severity and mortality to understand and counter the coronavirus invasion. 7, 8 Almost the only option for protection from animal virus pandemics, such as severe pandemic influenza A (H1N1) 2009 and COVID-19 caused by the new type of coronavirus (SARS-CoV-2), is that immune system works flawlessly in all stages of life. 4, 9, 10 In addition, natural antibodies, the product of the innate immune system, constitute the first barrier of organism defence. Anti-A1 and/or Anti-B IgM and IgG isohaemagglutinins are also natural antibodies of this innate immune system. 11 At this point, it is thought that immunohematology is an important guide in evaluating immune events (antigen-antibody reactions) associated with blood cells, especially natural antibodies against erythrocyte antigens.

The formation of antibodies that directly neutralise animal viruses or prevent them from binding to the cell surface receptor is insufficient in the elderly and some diseases with weak immune response such as common variable immunodeficiency (CVID) and autoimmunity or cancer. In this context, the use of convalescent immune plasma (CIP), which is thought to contain neutralising antibodies, is recommended. 12, 13 Early detection of individuals who cannot create an adequate immune response against the SARS-CoV-2 virus is of vital importance in the treatment of the disease. It is thought that this can be achieved practically by detecting the titre of anti-A1 and/ or Anti-B isohaemagglutinins as an expression of the innate immune system. In addition, it has recently been reported that Anti-A natural isohaemagglutinins can prevent the adhesion of viruses causing SARS to cells and accelerate complement-mediated neutralisation of viral particles. This idea was shaped by the recent reporting that anti-A natural isohaemagglutinins can inhibit the adhesion of viruses causing SARS to cells and accelerate complement-mediated neutralisation of viral particles. 14 In this study, it was aimed to investigate the relationship between isohaemagglutinins titres and routine biochemical parameters and disease morbidity/mortality of COVID-19 patients. In addition, the relationship between isohaemagglutinins, haemogram and biochemical parameters, age, use of CIP or erythrocyte suspension (ES) and disease morbidity and mortality were investigated.

Before the study, which was planned with a retrospective cohort, the records of approximately 15 440 patients hospitalised with diagnosis of COVID-19 according to the results of reverse transcription polymerase chain reaction (RT-PCR) test and/or thorax computed tomography between June and December 2020 were screened.

Among these patients, 286 patients who had a reverse blood grouping test (anti-A1 and anti-B IgM) were randomly selected for the study. The patients were divided into two groups as 148 patients with blood type A (Rh positive or negative) with anti-B IgM isohaemagglutinins in their plasma (anti-B group) and 138 patients with blood type B or O (Rh positive or negative) with anti-A1 IgM isohaemagglutinins (anti-A1 group). Anti-A1 and anti-B IgM isohaemagglutinins are not found in the blood type AB. For this reason, cases with blood type AB were excluded from study. Since anti-A1 IgM titres tend to be higher than anti-B IgM and to reach a sufficient population number, patients with blood type O containing two isohaemagglutinins were included in the anti-A1 group.

Ethical approval for the study was obtained from the University of Health Sciences Turkey Hamidiye Scientific Research Ethics Committee (2020-071).

RT-PCR test detected ORF1ab + N genes belonging to conserved regions of SARS-CoV-2 virus.

Anti-A1 or Anti-B IgM titration results for all patients included innate natural polysaccharide antibodies against A or B erythrocyte antigens detected by reverse blood grouping method (microplate direct haemagglutination method for ABO/Rh D blood grouping and typing, Neo Iris, Immucor, Inc., Germany). Anti-A1 and/or Anti-B IgM titrations were measured using the fully automated blood bank instrument (Neo Iris, Immucor, Inc., Germany).

• Isohaemagglutinins can be easily measured with the reverse blood typing test.

• Isohaemagglutinins are members of the innate immune system.

• There is no information about the relationship between isohaemagglutinins and the severity of COVID-19.

• High levels of isohaemagglutinins are associated with reduced rates of COVID-19 mortality.

• In addition, isohaemagglutinins are related with intensive care unit admission.

ABO isohaemagglutinins are mostly IgM class antibodies, although they are found in plasma as IgM, IgG and IgA. 15 Therefore, the results of titres for IgM class isohaemagglutinins were included in the study.

The range of anti-A and/or anti-B IgM titres was designated as 1/1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128 and 1/256. The endpoint titre was the highest dilution indicating a positive reaction score. That is, if the final titre is 1/256, this titre is expressed as the highest (expressed as 256) and if the final titre is 1/1, the titre is expressed as 1.

Since there is no similar study in the literature, post-hoc power analysis was performed using PS Power and Sample Size Calculations Version 3.0 instead of a priori power analysis. Since five independent variables were used for the binary logistic regression model, the sample size was calculated by taking at least 10 subjects for each independent variable. In the post-hoc power analysis performed according to the results of the anti-B IgM independent variable of the patients admitted and not admitted to the ICU, the power of the study was 0.867 (α = 0.05) and the effect size was 0.57 (Cohen d).

Similarly, the power of the study was 0.957 (α = 0.05) and the effect size was 0.65 according to the anti-A1 IgM independent variable results of the patients admitted and not admitted to the ICU.

Haemogram results (leukocyte count, neutrophil ratio, lymphocyte ratio, monocyte ratio, eosinophil ratio, basophil ratio, erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume (MCV), were used for all tests. The haemoglobin and biochemical data in the first 24-hour period were used for patients who were admitted to the clinic or intensive care unit (ICU) with diagnosis of COVID.

Age, gender and symptoms of all patients (loss of smell or taste, back or joint pain, muscle pain, cough, shortness of breath, fever, headache, weakness, sore throat, diarrhoea), chronic diseases, hospitalisation status, length of stay, oxygen support, intubation, ICU admission, ICU duration, CIP/ES treatment and discharge/exitus status records were collected. Anti-B and anti-A1 groups were compared primarily in terms of gender and age, as differences and other limitations between groups would reduce significance. GraphPad Statistics software were used. In the study, the unpaired t test was used to compare parametric data of independent groups with two groups, and the Mann-Whitney test was used to compare nonparametric data. To determine the effectiveness and odds ratio (OR) of independent variables such as anti-A1 IgM, anti-B IgM, neutrophil to lymphocyte ratio (NLR), D-dimer, CRP and age, which are thought to influence ICU or exitus status, binary logistic regression analysis was used. To evaluate the diagnostic power of Anti A1 and anti-B IgM, which are indicators of the innate immune system, related to ICU admission and exitus status, Receiver Operating Characteristic (ROC) analysis was used. The chi-square test was used to evaluate categorical data.

Of the 286 patients between the ages of 18-97 included in the study, The demographic results of patients with COVID-19 according to their clinical or ICU treatment status are given in Table 1 . The patients who received treatment in ICU had higher age, chronic disease, CT finding, hospital stay, use of ES and CIP, and respiratory distress (P < .01). There was no difference between the clinical and ICU treatment in terms of blood types and gender (P > .05). It was noteworthy that all patients who were exitus were intensive care patients. Haemogram, sedimentation and biochemical test results are compared in Tables 2 and 3 according to the treatment received by patients in the clinic (n:145) and ICU (n:141) without being divided into study groups. Leukocyte count, neutrophils ratio, NLR, RDW, MPV and ESR values were higher in patients admitted to ICU, while lymphocyte ratio, monocyte ratio, eosinophil ratio, basophil ratio, erythrocyte count, haemoglobin, haematocrit, platelet count and PCT values were lower (P < .05). While glucose, urea, creatinine, AST, GGT, LDH, Na, CRP, procalcitonin, prothrombin time, INR and D-dimer levels were higher in those who admitted to ICU, eGFR, albumin and Ca levels were lower (P < .05). There was no difference between the groups in terms of ALT, ALP, CK, K and fibrinogen levels (P > .05).

In the ROC curve analysis using the anti-B IgM titres to distinguish between patients in anti-B group receiving treatment in clinic (n: 78) and ICU (n: 70), the sensitivity for anti-B IgM at cut-off ≤4 was 71.4%, specificity 67.9% and area under the curve (AUC) 0.757 (P < .0001) ( Figure 5A ). In the same group, in the analysis to distinguish between exitus (n: 45) and discharged patients (n:103), the sensitivity of anti-B IgM titres at cut-off ≤4 was found to be 88.9%, specificity 66.0% and AUC 0.831 (P < .0001) ( Figure 5B ).

In the ROC curve analysis using the anti-A1 IgM titres to distinguish between patients in anti-A1 group receiving treatment in clinic (n:67) and ICU (n:71), the sensitivity of anti-A1 IgM at cut-off ≤4 was 62.0%, specificity 76.1% and area under the curve (AUC) 0.761 (P < .0001) ( Figure 5C ). In the same group, the analysis to distinguish between exitus (n:44) and discharged patients (n: 94) found the sensitivity of anti-A1 IgM titres at cut-off ≤4 was 79.6%, specificity 73.4% and AUC 0.861 (P < .0001) ( Figure 5D ).

Binary regression analysis to determine the effect of five independent variables, consisting of Anti-A1 or anti-B IgM, NLR, D-dimer, CRP and age, on dependent variables (ICU admission and exitus status) as indicators of disease severity are given in Tables 4 and 5 . Although the model with five independent variables for predicting both ICU admission and exitus status in the anti-B group seems appropriate in total (Omnibus Test, P < .0001 and Hosmer-Lemeshow test, P > .05), the effects of CRP and age in the models for both conditions were statistically insignificant (P > .05). Similarly, in the anti-A1 group, the model The fact that the Nagelkerke R2 values given in Tables 4 and 5 for both groups were 0.535 and 0.392 for ICU admission and 0.600 and 0.526 for exitus status, respectively, demonstrates that the twovariable models explained the dependent variables (ICU admission and exitus status) at a good level. In addition, the following formula 

The discussions about the related COVID-19 disease are especially centred around the angiotensin-converting enzyme 2 (ACE2) receptor, senility, inappropriate immune response and the chronic disease paradigm. 16, 17 In most patients, chronic diseases cause recurrent infections, by reducing resistance against viral or bacterial pathogens.

In addition, this deterioration in the immune system may cause autoimmune diseases and cancers due to impaired immunological tolerance of the body against its own cells. 12, 18, 19 Therefore, the immune system response should be the primary focus in combating COVID-19 disease.

The COVID-19 pandemic is characterised by an inadequate polysaccharide antibody response. Isohaemagglutinins, which are with AB blood group antigens. 3, 12, 20, 21 IgM antibodies secreted by B1 cells, which play an important role in innate immunity, are the dominant antibodies during primary threat. While participating in the neutralisation and cleaning of pathogens, they also initiate inflammatory reactions against pathogens. The innate immune system also stimulates the acquired immune system, which creates the humoral immune response. Thus, the pathogen is stopped more strongly and specifically. Isohaemagglutinins and pneumococcal polysaccharide antibody titres, which are currently used as indicators of natural antibodies, are used as a measure to assess defects in this immune response. 11, 20, [22] [23] [24] The routine use of isohaemagglutinins for the detection of suspected immunodeficient patients is still under discussion. Based on this information, we used anti-A1 and anti-B IgM antibodies, which are indicators of the effectiveness of the innate immune system, to predict severe cases of COVID-19 disease in this study.

In this study, patients with COVID-19 who received ICU treatment had higher leukocyte, neutrophil, NLR, urea, creatinine, albumin, CRP, . .0015 ** Nonparametric data are given as mean, standard deviation and median (min-max). If P value is less than .005, the difference is significant. While parametric data were given as mean and standard deviation, nonparametric data were given as mean, standard deviation and median (min-max). If P value is less than .005, the difference is significant. Moreover, the effect of the age variable in the model may have been limited by the isohaemagglutinins because anti-A1 and anti-B IgM isohaemagglutinins antibodies are biomarkers that tend to decrease with age. Another variable that was found to be partially ineffective in the regression model was D-dimer. D-dimer is a small protein found in the F I G U R E 5 ROC analysis for A, anti-B IgM to distinguish between the ICU admission, or not. B, Anti-B IgM to distinguish between the patients with exitus, or not. C, Anti-A1 IgM to distinguish between the ICU admission, or not. D, Anti-A1 IgM to distinguish between the patients with exitus, or not. As a result of the analysis, the most suitable cut-off value was found to be ≤4. At this cut-off value, sensitivity, specificity and area under the curve (AUC) results of anti-B and anti-A1 IgM are seen. Anti-B and anti-A1 IgM had good sensitivity and specificity in diagnostic power for the severity of COVID-19 In COVID, which is used as a reference for immune system failure, and some pathologies (such as splenectomy, immunosuppression and acquired immunodeficiency, HIV, autoimmunity, or aging) with impaired immune response, reduction, or absence of anti-A and/or anti-B isohaemagglutinins and poor polysaccharide antibody response to vaccines are expected. 20, 28, 29 Assessment of this impaired immunological response is possible by detecting pneumococcal polysaccharide antibody response and isohaemagglutinins levels, although these are still under discussion. Of these, isohaemagglutinins were chosen in our study because they are more accessible and practical. In the study conducted considering the above information, the fact that the patients with low isohaemagglutinins levels were 65 years and older and most of them had chronic disease was interpreted in favour of low immune system response in these patients. This situation is a sign that this population will need multiple therapies such as antiviral and complex vitamins, oxygen supplementation, CIP, early Ig and interferon β and/or γ therapies support to support the immune system. 30, 31 However, in our study, the mortality rate was found to be high, even though a significant portion of the elderly population with low isohaemagglutinins levels was treated in the ICU and received multiple therapies. The probable reason for this is that patients who are likely to have severe disease and who will need additional therapies cannot be identified in the early period. Moreover, the lack of expected effect from CIP treatment was not yet explained. In general, this situation may be attributed to the lack of early treatment and the lack of sufficient antibodies in CIP to provide viral neutralisation. Therefore, isohaemagglutinins, which are indicators of innate immune response, may be used for the prediction of disease severity in the early period.

Age-related insensitivity of the immune system to most of the current vaccines is attributed to newly formed neo-antigens that the immune system cannot recognise and the decrease in the number and functions of T and B cells involved in this recognition. 12 

A or B antigens. 15, 37 Therefore, in the group evaluated with anti-A1

IgM, high values due to anti-A, B reactivity can be observed. However, since the study was conducted in two different groups, the effect of this negativity on the results was limited.

In a study examining the relationship between ABO blood group type and COVID-19, researchers suggested that individuals with blood type O are more resistant to the disease and that anti-A and anti-B antibodies may contribute to viral neutralisation by binding to antigens on the viral envelope. 14 Unlike these researchers, in our study, no relationship was found between the blood group type and the mortality status. In another study by Guillon et al, 38 it was reported that monoclonal or naturally occurring anti-A antibodies inhibit the interaction between the SARS-CoV S protein and ACE2R depending on the dose, which is close to our study findings. However, our findings were not intended to show that isohaemagglutinins may directly target the S protein. In short, we suggested that isohaemagglutinins levels are related with resistance to COVID-19 disease rather than the blood group types.

Few studies have been conducted about the diagnostic value of isohaemagglutinins antibody deficiency. Although there are conflicting data, it was reported that it can be used for the diagnosis of immunodeficiency such as congenital immunologic deficiency syndromes, CVID and Wiskott-Aldrich syndrome, or to check the restoration of immunological competence. 11, 20, 39 Basically, the results obtained from our study showed that isohaemagglutinins are satisfactory in predicting the severity of COVID-19. If this function can be combined with a second parameter that activates the acquired immune system, such as NK-cell activity which measures the innate immune system's ability to function or NLR, 4,5 more effective results will be achieved in predicting the severity of COVID disease.

In conclusion, anti-A1 and anti-B IgM isohaemagglutinins, which are expressions of the innate immune system, can be used alone or in combination with NLR for predicting the severity and mortality of COVID-19.

We would like to thank all hemovigilance and laboratory staff working at Sultan 2. Abdulhamid Han Training and Research Hospital Blood Center.

The authors declare that they have no conflicts of interest. The authors did not receive support from any organisation. 

Pathogen recognition and inflammatory signaling in innate immune defenses

Pathogen recognition by the innate immune system

Structure and function of immunoglobulins

Target-induced natural killer cell loss as a measure of NK cell responses

Innate immune sensing of coronavirus and viral evasion strategies

Biomarkers associated with COVID-19 disease progression

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

IgA bad IgG in SARS-CoV-2 infection?

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Natural antibodies -facts known and unknown

Comparison of diagnostic criteria for common variable immunodeficiency disorder

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike

Association between ABO blood groups and risk of SARS-CoV-2 pneumonia

Anti-A and anti-B: what are they and where do they come from?

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Infections in 252 patients with common variable immunodeficiency

Mechanisms leading to autoantibody production: link between inflammation and autoimmunity

Value of allohaemagglutinins in the diagnosis of a polysaccharide antibody deficiency

Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development

Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes

Emerging functions of natural IgM and its Fc receptor FCMR in immune homeostasis

Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in apache children

Hematologic parameters in patients with COVID-19 infection

Mild versus severe COVID-19: laboratory markers

Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis

HIV-1 and influenza antibodies: seeing antigens in new ways

Practice parameter for the diagnosis and management of primary immunodeficiency

Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A-and Bspecific immunoaffinity chromatography: industry-scale assessment

Use of immune modulator interferon-gamma to support combating COVID-19 pandemic Stoleski S, ed

Ageing and infection

A comparative review of aging and B cell function in mice and humans

The transcriptional landscape of age in human peripheral blood

mRNA vaccines -a new era in vaccinology

Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning

ABO-blood-group-related idiotypic network: mimicry of oligosaccharide epitope by rabbit antiidiotypic antibodies to murine monoclonal anti-A antibody

Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by antihisto-blood group antibodies

A multiinstitutional survey of the Wiskott-Aldrich syndrome

Assessment of severity and mortality of COVID-19 with anti-A1 and anti-B IgM isohaemagglutinins, a reflection of the innate immune status